Walleye Capital
NRIX icon

Walleye Capital’s Nurix Therapeutics NRIX Stock Holding History

Walleye Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
+15,568
New +$265K ﹤0.01% 2982
2026
Q1 		– Sell
-74,869
Closed -$1.42M – 4781
2025
Q4 		$1.42M Buy
+74,869
New +$1.08M ﹤0.01% 2155
2025
Q3 		– Sell
-62,298
Closed -$710K – 4920
2025
Q2 		$710K Sell
62,298
-11,762
-16% -$127K ﹤0.01% 2335
2025
Q1 		$880K Buy
+74,060
New +$1.24M ﹤0.01% 2077
2024
Q3 		– Sell
-24,882
Closed -$519K – 5701
2024
Q2 		$519K Buy
+24,882
New +$387K ﹤0.01% 3482
2021
Q4 		– Sell
-10,546
Closed -$316K – 2249
2021
Q3 		$316K Buy
+10,546
New +$325K 0.01% 990

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Walleye Capital's NRIX Position: Q2 2026 in Review

Walleye Capital opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 15,568 shares worth $378K. The stake represents ﹤0.01% of the portfolio and ranks #2982 among its holdings. This is a return to the name: Walleye Capital previously reported a position in NRIX as recently as Q4 2025.

Walleye Capital first reported a position in NRIX in Q3 2021 and has held it in 6 quarters since. The position peaked at $1.42M in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Walleye Capital held 15,568 shares of Nurix Therapeutics worth $378K as of Q2 2026.
  • Nurix Therapeutics was a new Walleye Capital position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2982 holding.
  • Walleye Capital first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Walleye Capital's Nurix Therapeutics position peaked at $1.42M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.